Stayble has, together with APL, completed manufacturing of the investigational drug for the upcoming clinical phase 2b study.
The Company announces that the investigational drug (two doses of STA363 and placebo) now is manufactured and quality assured by our partner APL.CEO Andreas Gerward comments: The completion of the investigational drug is another valuable piece in the jigsaw for initiating our upcoming phase 2b study. We are now awaiting the approval of our previously submitted applications in the Netherlands, Spain and Russia, while we monitor the development of the COVID-19 situation and its impact on the study’s start date. The goal of the clinical phase 2b trial is to demonstrate safety, tolerability